Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-04
2005-01-04
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S176000, C546S233000
Reexamination Certificate
active
06838468
ABSTRACT:
Compounds of general formula I[Chemical formula should be inserted here. Please see paper copy] R1is selected from any one of phenyl, pyridinyl, pyrrolyl, thienyl, furanyl, imidazolyl, triazolyl, and pyridine N-oxide; where each R1phenyl ring and R1heteroaromatic ring may optionally and independently be further substituted by 1,2 or 3 substituents selected from straight and branched C1-C6alkyl, NO2, CF3, C1-C6alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders.
REFERENCES:
patent: 2898339 (1959-08-01), Wheeler et al.
patent: 4581171 (1986-04-01), Kennis et al.
patent: 4816586 (1989-03-01), Portoghese
patent: 4939137 (1990-07-01), Russell et al.
patent: 5140029 (1992-08-01), Kennis et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5683998 (1997-11-01), Shibayama et al.
patent: 6187792 (2001-02-01), Delorme et al.
patent: 6455545 (2002-09-01), Delorme et al.
patent: WO 9315062 (1993-08-01), None
patent: WO 9723466 (1997-07-01), None
patent: WO 9828275 (1998-07-01), None
patent: WO 9933806 (1999-07-01), None
patent: WO 0174804 (2001-10-01), None
patent: WO 0174806 (2001-10-01), None
patent: WO 2002094811 (2002-11-01), None
Bilsky, et al., SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995).
Takemori, et al., “Selective Natrexone-Drived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).
Barber, et al., “Antinociceptive Effects of the 5-HT Antagonist Ritanserin in Rats: Evidence for an Activation . . . in the Spinal Cord,” Neuroscience Letters 99:234-238 (1989).
Greene, “Protective Groups in Organic Synthesis,” Wiley & sons, pp. 218, 220, 232, 233, 251 (1982).
Wei, et al., “N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl) . . . and its Analogues,” J. Med. Chem. 43:3895-3905 (2000).
Zhang, et al., “Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 42:5455-5463 (1999).
Brown William
Walpole Christopher
Wei Zhong-yong
AstraZeneca AB
Seaman D. Margaret
Shen Jianzhong
LandOfFree
4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378135